International Stem CellISCO -5.03%24 Shareholder Yield % is 16.11% as of Mar. 2026, which is 671% above its 10-year median of 2.09. GuruFocus rates ISCO with a GF Score™ of 24/100 and a GF Value™ of $0.13 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,294 Biotechnology companies, International Stem Cell ranks better than 96.21% on this metric.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return.
As of today, International Stem Cell's Shareholder Yield % was 16.11%.
International Stem Cell (OTCPK:ISCO) Shareholder Yield % Explanation
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."
Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.
Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.
International Stem Cell Shareholder Yield % Related Terms
International Stem Cell Shareholder Yield % Historical Data
* Premium members only.
The historical data trend for International Stem Cell's Shareholder Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ISCO vs ZVSA, AXIM, HEPA: Shareholder Yield % Comparison
For the Biotechnology subindustry, International Stem Cell's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
International Stem Cell Shareholder Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, International Stem Cell's Shareholder Yield % distribution charts can be found below:
* The bar in red indicates where International Stem Cell's Shareholder Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
International Stem Cell (ISCO) has a Shareholder Yield % of 16.11% as of Mar. 2026. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on International Stem Cell and its competitors. This is 671% above median its historical median of 2.09. According to the industry distribution chart, International Stem Cell ranks #49 out of 1294 companies in the Biotechnology industry, placing it in the top 3.8%.
Is International Stem Cell's Shareholder Yield % too high?
International Stem Cell's current Shareholder Yield % of 16.11% is 671% above median its 10-year median of 2.09. Based on the distribution chart, International Stem Cell ranks #49 out of 1294 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, International Stem Cell has a GF Score™ of 24/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does International Stem Cell's Shareholder Yield % compare to ZVSA and AXIM?
According to the Biotechnology industry distribution chart, International Stem Cell ranks #49 out of 1294 companies for Shareholder Yield %. This places International Stem Cell in the top 4% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Biotechnology company?
A good Shareholder Yield % depends on the Biotechnology industry context. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on International Stem Cell and its competitors. International Stem Cell's current Shareholder Yield % is 16.11%, which is 671% above median its own 10-year median of 2.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is International Stem Cell stock overvalued right now?
Based on GuruFocus' analysis, International Stem Cell (ISCO) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.13, compared to a current price of $0.17 — trading 30.8% above its estimated fair value. The current Shareholder Yield % is 16.11%, which is 671% above median its 10-year median of 2.09. International Stem Cell's overall GF Score™ is 24/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For International Stem Cell (ISCO), the current Shareholder Yield % is 16.11% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is International Stem Cell (ISCO) Overvalued in 2026?
Based on GuruFocus' analysis, International Stem Cell stock appears to be overvalued.
The current stock price of $0.17 is trading 30.8% above its estimated GF Value™ of $0.13.
GuruFocus considers International Stem Cell to be Significantly Overvalued.
Key valuation signals for ISCO:
Shareholder Yield %: 16.11% (671% above median its 10-year median of 2.09)
GF Value™: $0.13 vs. price of $0.17 (30.8% above fair value)
No single metric tells the full story. See the ISCO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
International Stem Cell Corp is a clinical-stage biotechnology company. It is focused on therapeutic and biomedical product development with multiple long-term therapeutic opportunities. The company develops different cell types from its stem cells that may result in therapeutic products. The clinical applications of the company include neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; Liver cells, which are used to treat a variety of congenital and acquired liver diseases; and retinal cells and three-dimensional eye structures. The company operates in three segments, the therapeutic market, the biomedical market, and the anti-aging market. The Biomedical products business segment accounts for the majority of revenue.
24GF Score
Get the complete analysis for ISCO
Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISCO has been successfully added to your 
